Luly Jay R. → ENANTA PHARMACEUTICALS INC ENTA

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 20/100 · Filer 90d Win Rate: 0% · Hist. 90d Edge: -10.8%

Passive Schedule 13G filer baseline
Held by 1 tracked 13F institutional manager
Elevated short days-to-cover (8.6 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

3 13D/G filings on this issuer

2 other filings besides this one

Filer Track Record

2 filings by this filer

1 other filing in the data moat

Short Interest · settle 2026-10-15

DTC 8.57

2,265,069 shares short · -11.3% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $6.92M

Point72 Asset Mgmt

Other 13D/G Filings on ENANTA PHARMACEUTICALS INC

Filed	Form	Filer	Stake	Shares
2026-10-27	SCHEDULE 13G	BlackRock Portfolio Management LLC	—	—	view →
2025-02-14	SCHEDULE	Luly Jay R.	7.70%	1,703,616	view →

Other Filings by Luly Jay R.

Filed	Form	Issuer	Stake	Shares
2025-02-14	SCHEDULE	ENANTA PHARMACEUTICALS INC ENTA	7.70%	1,703,616	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →